Product Overview
[Drug Name]
Generic Name: Indapamide Tablets
Trade Name: YiDaAn Indapamide Tablets 2.5mg*60 Tablets
Pinyin Code: YiDaAn ZuoDaPaAnPian 2.5mg*60 Tablets
[Main Ingredient]
Indapamide.
[Properties]
This product is a sugar-coated tablet, which appears white after removing the sugar coating.
[Indications/Main Functions]
Essential Hypertension
[Precautions]
1. To reduce the possibility of electrolyte imbalance, a smaller effective dose should be used. Regular monitoring of serum potassium, sodium, and uric acid levels is recommended to maintain fluid and electrolyte balance, and potassium supplementation should be performed promptly. 2. When used as a diuretic, it is best to administer the drug once daily in the morning to avoid having to urinate during the night. 3. Anuria or severe renal insufficiency may induce azotemia. 4. In patients with gout or hyperuricemia, serum uric acid may be further elevated. 5. In patients with hepatic insufficiency, diuresis may precipitate hepatic coma. 6. After sympathectomy, the antihypertensive effect may be enhanced. 7. If surgery is required while using this drug, it is not necessary to discontinue use, but the anesthesiologist must be informed. Please read the package insert carefully and follow the doctor's instructions.
[Drug Interactions]
Sulfonamide allergy, severe renal insufficiency, hepatic encephalopathy or severe hepatic insufficiency, and hypokalemia.
[Pediatric Use]
Unclear information available.
[Elderly Use]
Elderly individuals are more sensitive to antihypertensive effects and electrolyte changes and often experience changes in renal function; therefore, caution is advised when using this drug.
[Pregnant and Lactating Women]
Human studies are lacking regarding the effects on pregnancy, and animal studies have not revealed any issues. Whether this drug is excreted into breast milk is unknown, but no issues have been reported in humans.
[Specifications]
2.5mg x 60 tablets
[Dosage and Administration]
Usual adult dose: one tablet orally, once daily.
[Adverse Reactions]
Mild, transient, and dose-related. 1. Less common symptoms include: diarrhea, headache, loss of appetite, insomnia, nausea, and orthostatic hypotension. 2. Less common symptoms include: allergic reactions such as rash and itching; hyponatremia, hypokalemia, and hypochloremic alkalosis.
[Contraindications]
Sulfonamide allergy, severe renal insufficiency, hepatic encephalopathy or severe hepatic insufficiency, and hypokalemia.
[Overdose]
1. No toxic effects have been observed with doses up to 40 mg, which is 16 times the therapeutic dose. The primary symptoms of acute poisoning are fluid and electrolyte imbalances (hypotension and hypokalemia). Possible clinical symptoms include nausea, vomiting, hypotension, cramps, drowsiness, confusion, and polyuria, oliguria, or even anuria (due to hypovolemia). 2. Measures to be taken: First, rapidly eliminate the ingested drug, which can be achieved through gastric lavage or administration of activated charcoal. Then, seek medical attention to correct fluid and electrolyte imbalances until normal.
[Pharmacology and Toxicology]
1. It is a sulfonamide diuretic that acts by inhibiting water and electrolyte reabsorption in the diluent segment of the distal renal tubular cortex. Its antihypertensive effect is unclear, and its diuretic effect cannot explain its antihypertensive effect because the antihypertensive effect occurs at doses far lower than those with diuretic effects. Possible mechanisms include: regulation of calcium influx into vascular smooth muscle cells; stimulation of the synthesis of prostaglandins PGE2 and PGI2; and reduction of vascular hypersensitivity to vasopressors, thereby inhibiting vasoconstriction. 2. This drug has little or no effect on cardiac output, heart rate, and rhythm when used to lower blood pressure. Long-term use rarely affects glomerular filtration rate or renal blood flow. This drug does not affect lipid and carbohydrate metabolism.
[Pharmacokinetics]
1. Oral absorption is rapid and complete, with a bioavailability of 93%, unaffected by food. Plasma binding is 71-79%, and it also binds to elastin in vascular smooth muscle. Peak plasma concentrations are reached 1-2 hours after oral administration. 2. Peak antihypertensive effect occurs approximately 24 hours after a single oral dose; after repeated dosing, peak effect is achieved in approximately 8-12 weeks, with duration of effect lasting 8 weeks. The half-life is 14-18 hours. Metabolism occurs in the liver, producing 19 metabolites. Approximately 70% is excreted via the kidneys, 7% unchanged, and 23% via the gastrointestinal tract. Pharmacokinetic parameters are unchanged in patients with renal failure.
